synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
== See also == Drilosphere, the part of the soil influenced by earthworm secretions and castings The Formation of Vegetable Mould through the Action of Worms, an 1881 book by Charles Darwin Soil life Vermicompost Vermifilter Vermifilter toilet Worm charming
=== Transferring a hydride and releasing a proton === Sometimes a dehydrogenase catalyzed reaction will look like this: AH + B+ ↔ A+ + BH when a hydride is transferred. A represents the substrate that will be oxidized, while B is the hydride acceptor. Note how when the hydride is transferred from A to B, the A has taken on a positive charge; this is because the enzyme has taken two electrons from the substrate in order to reduce the acceptor to BH. The result of a dehydrogenase catalyzed reaction is not always the acquisition of a positive charge. Sometimes the substrate loses a proton. This may leave free electrons on the substrate that move into a double bond. This happens frequently when an alcohol is the substrate; when the proton on the oxygen leaves, the free electrons on the oxygen will be used to create a double bond, as seen in the oxidation of ethanol to acetaldehyde carried out by alcohol dehydrogenase in the image on the right. Another possibility is that a water molecule will enter the reaction, contributing a hydroxide ion to the substrate and a proton to the environment. The net result on the substrate is the addition of one oxygen atom. This is seen for example in the oxidation of acetaldehyde to acetic acid by acetaldehyde dehydrogenase, a step in the metabolism of ethanol and in the production of vinegar.
The early or fulminant form of hemorrhagic smallpox (referred to as purpura variolosa) begins with a prodromal phase characterized by a high fever, severe headache, and abdominal pain. The skin becomes dusky and erythematous, and this is rapidly followed by the development of petechiae and bleeding in the skin, conjunctiva and mucous membranes. Death often occurs suddenly between the fifth and seventh days of illness, when only a few insignificant skin lesions are present. Some people survive a few days longer, during which time the skin detaches and fluid accumulates under it, rupturing at the slightest injury. People are usually conscious until death or shortly before. Autopsy reveals petechiae and bleeding in the spleen, kidney, serous membranes, skeletal muscles, pericardium, liver, gonads and bladder. Historically, this condition was frequently misdiagnosed, with the correct diagnosis made only at autopsy. This form is more likely to occur in pregnant women than in the general population (approximately 16% of cases in unvaccinated pregnant women were early hemorrhagic smallpox, versus roughly 1% in nonpregnant women and adult males). The case fatality rate of early hemorrhagic smallpox approaches 100%.
The land-grant universities and the Chile Pepper Institute promote the use of cultivars as the most sustainable and environmentally safe disease control method both in terms of economics and long-term environmental perspective. Notable cultivars include 'Early Jalapeño', 'TAM Mild Jalapeño', 'TAM Mild Jalapeño II', 'TAM Veracruz', the yellow 'TAM Jaloro', 'NuMex Vaquero', the colorful 'NuMex Piñata', 'TAM Dulcito', 'Waialua', Biker Billy and 'NuMex Primavera'. Sweet hybridized varieties have been created with no "heat", although they retain the appearace and flavor of a jalapeño.
A study assessed urinary levels of pregnanediol glucuronide, the major metabolite of progesterone in urine, and found that although circulating progesterone levels and urinary levels of pregnanediol glucuronide increased after treatment with transdermal progesterone, the levels of both nonetheless remained in the range of the follicular phase and hence were very low. A case report found that the 5α-reductase inhibitor finasteride did not increase the circulating progesterone levels or urinary pregnanediol glucuronide levels produced by transdermal progesterone. Likewise, a study found that the 5α-reductase inhibitor dutasteride resulted in only slightly higher progesterone levels with transdermal progesterone. Finally, 5α-reductase is also a major enzyme involved in the metabolism of testosterone, yet transdermal testosterone is approved for androgen replacement therapy and is very effective in raising testosterone levels. In terms of elimination, a study that investigated the pharmacokinetics of transdermal progesterone using either a hydrophilic-, lipophilic-, or emulsion-type base found that in all three cases the elimination half-life was in the range of 30 to 40 hours.
Sources: en.wikipedia.org
=== 3 March === The SAF reached the eastern edge of the al-Manshia bridge in East Nile, Khartoum and retook the headquarters of the East Nile Central Reserve Forces. Seven people were killed in an SAF airstrike on Umm Kuraydim, north of El Obeid.
The Clinical Hemostasis Handbook. Chicago: Year Book Medical Publishers. Laposata, M. (2010–2013). Coagulation Disorders. Quality in Laboratory Diagnosis series. New York: Demos Medical Publishing. Laposata was also editor of the full six-volume series (Laboratory Management, Clinical Microbiology, Transfusion Medicine, Clinical Chemistry, Hematology/Clinical Immunology, and Coagulation Disorders). Laposata, M. (2016). Clinical Diagnostic Tests: How to Avoid Errors in Ordering Tests and Interpreting Results. New York: Demos Medical Publishing. Laposata, M.; McCaffrey, P. (2022). Clinical Laboratory Methods: Atlas of Commonly Performed Tests and Molecular Test Methods. New York: McGraw-Hill. Laposata, M., ed. (2025). Laposata's Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory (4th ed.). Lange Series. New York: McGraw-Hill. Laposata, M.; Dighe, A. S. (2007). "'Pre-pre' and 'post-post' analytical error: High-incidence patient safety hazards involving the clinical laboratory." Clinical Chemistry and Laboratory Medicine. 45: 712–719. Laposata, M. (2014). "Putting the patient first: Using the expertise of laboratory professionals to produce rapid and accurate diagnoses." Laboratory Medicine. 45: 4–5. Graber, M. L.; Rusz, D.; Jones, M. L.; Farm-Franks, D.; Jones, B.; Cyr Gluck, J.; Thomas, D. B.; Gleason, K.; Welte, K.; Abfalter, J.; Westerhaus, K.; Adams, G.; Laposata, M.; Eichbaum, Q.; Nabatchi, T.; Compton, M. (2017). "The new diagnostic team." Diagnosis. 4: 225–238.
== Synthesis == Shortly after Merck initiated research into reducing the severity and likelihood of chemotherapy-induced nausea and vomiting, researchers discovered that aprepitant is effective in prevention. Researchers worked on coming up with a process to create aprepitant, and within a short period they came up with effective synthesis of the substance. This original synthesis was deemed to be workable and proved to be a crucial step in achieving commercialization; however, Merck decided that the process was not environmentally sustainable. This was due to the original synthesis requiring six steps, many of which needed dangerous chemicals such as sodium cyanide, dimethyltitanocene, and gaseous ammonia. In addition to this, for the process to be effective cryogenic temperatures were needed for some of the steps and other steps produced hazardous byproducts such as methane. The environmental concerns of the synthesis of aprepitant became so great that Merck research team decided to withdraw the drug from clinical trials and attempt to create a different synthesis of aprepitant. The gamble of taking the drug out of clinical trials proved to be successful when shortly afterwards the team of Merck researchers came up with an alternative and more environmentally friendly synthesis of aprepitant. The new process works by four compounds of similar size and complexity being fused together. This therefore is a much simpler process and requires only three steps, half the number of the original synthesis.
Initial clinical trial results with IgG4 PD1 antibody nivolumab were published in 2010. It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first-line setting, but is FDA-approved in subsequent lines of therapy. Pembrolizumab (Keytruda) is another PD1 inhibitor that was approved by the FDA in 2014. Pembrolizumab is approved to treat melanoma and lung cancer. Antibody BGB-A317 is a PD-1 inhibitor (designed to not bind Fc gamma receptor I) in early clinical trials.
=== Rocks === These are asteroids and other non-planetary bodies hollowed out for habitation and usually spun for centrifugal artificial gravity. Rocks (with the exception of those used for secretive purposes) are described as having faster-than-light space drives, and thus can be considered a special form of spaceship. Like Orbitals, they are usually administered by one or more Minds. Rocks do not play a large part in most of the Culture stories, though their use as storage for mothballed military ships (Pittance) and habitats (Phage Rock, one of the founding communities of the Culture) are both key plot points in Excession.
Sources: en.wikipedia.org
== See also == Drug disposal – Safe disposal of unused drugs Electronic waste – Discarded electronic devices Human waste – Feces and urine List of waste management topics List of waste types Incineration – Waste treatment process Universal precautions – Medical standard for contact avoidance
Glycolysis was the first metabolic pathway discovered: As glucose enters a cell, it is immediately phosphorylated by ATP to glucose 6-phosphate in the irreversible first step. In times of excess lipid or protein energy sources, certain reactions in the glycolysis pathway may run in reverse to produce glucose 6-phosphate, which is then used for storage as glycogen or starch. Metabolic pathways are often regulated by feedback inhibition. Some metabolic pathways flow in a 'cycle' wherein each component of the cycle is a substrate for the subsequent reaction in the cycle, such as in the Krebs Cycle (see below). Anabolic and catabolic pathways in eukaryotes often occur independently of each other, separated either physically by compartmentalization within organelles or separated biochemically by the requirement of different enzymes and co-factors.
These effects were not noted in its medicinal use in the 1950s and 1960s, and reports of physical violence on PCP have often been shown to be unfounded. Recreational doses of the drug also occasionally appear to induce a psychotic state, with emotional and cognitive impairment that resembles a schizophrenic episode. Users generally report feeling detached from reality. Symptoms are summarized by the mnemonic device RED DANES: rage, erythema (redness of skin), dilated pupils, delusions, amnesia, nystagmus (oscillation of the eyeball when moving laterally), excitation, and skin dryness.
== History == It was approved in the United States in 2018 based on data from two phase III studies on reversing the anticoagulant activity of FXa inhibitors rivaroxaban and apixaban in healthy volunteers. As a condition of its accelerated approval, the ANNEXA-I study was conducted comparing it to other currently used reversal agents ("usual care"). Andexanet alfa was voluntarily withdrawn from the market by the manufacturer following safety concerns expressed by the FDA. Production and distribution was ended December 22, 2025.
== External links == Goudarzi, Sara (9 June 2006). "Yogurt Culture Evolves". LiveScience. Archived from the original on August 29, 2008. Retrieved 2013-01-14. Type strain of Lactobacillus delbrueckii subsp. bulgaricus at BacDive - the Bacterial Diversity Metadatabase "Lactobacillus delbrueckii". microbewiki.kenyon.edu – Microbe Wiki. Retrieved 2019-11-14.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.